ArticleClinical, cosmetic and investigational dermatology2024

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study.

Matteo Megna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.